Following a supply shortage, GlaxoSmithKline Consumer Healthcare says 2 mg and 4 mg Nicorette mini Lozenge are now available atmost retail shelves in the U.S., according to a company press release.
In February 2014, GlaxoSmithKline voluntarily recalled all nicotine lozenges from warehouses and distributors manufactured at a site in Aiken, S.C. after manufacturing issues affecting some batches were detected. In some cases, the lozenges were larger or smaller than GSKCH's manufacturing standards.
After a comprehensive assessment and complex testing process to correct manufacturing issues and improve quality measures, production of Nicorette mini Lozenge has resumed.
"The safety and well-being of our consumers is our number one priority and we did not compromise on the somewhat lengthy corrective actions that needed to be taken," said Sue Kelsey, GlaxoSmithKline Consumer Healthcare Marketing Director, Wellness & Skin Health Brands. "We understand what a life-changing event stopping smoking can be and, at the same time, how incredibly difficult it can be to get there. For those looking for help, we hope that the return to market of Nicorette mini Lozenge and our online information can help to provide the tools and inspiration to get smokers towards their goals."
